Remaxol® in Mechanical Jaundice of Non-malignant Origin
Status:
Completed
Trial end date:
2020-04-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of Remaxol (succinate +
methionine + inosine + nicotinamide; POLYSAN Ltd., Russia) infusions at dose 400 and 800 ml
to treat mechanical jaundice of non-tumor cause during the first week after surgery.